

PRODUCT INFORMATION



Glucose-dependent Insulinotropic Peptide (22-51) (human) (trifluoroacetate salt)

Item No. 36968

Formal Name: L- α -glutamyl-L-lysyl-L-lysyl-L- α -glutamylglycyl-L-histidyl-L-phenylalanyl-L-seryl-L-alanyl-L-leucyl-L-prolyl-L-seryl-L-leucyl-L-prolyl-L-valylglycyl-L-seryl-L-histidyl-L-alanyl-L-lysyl-L-valyl-L-seryl-L-seryl-L-prolyl-L-glutamyl-L-prolyl-L-arginylglycyl-L-prolyl-L-arginine, trifluoroacetate salt

Synonyms: GIP (22-51), Gastric Inhibitory Peptide (22-51)

Peptide Sequence: EKKEGHFSALPSLPVGS~~HAKVSSP~~QPRGPR-OH

MF: C₁₄₀H₂₂₆N₄₄O₄₁ • XCF₃COOH

FW: 3,181.6

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years

H—Glu—Lys—Lys—Glu—Gly—His—Phe—Ser—Ala—Leu—
Pro—Ser—Leu—Pro—Val—Gly—Ser—His—Ala—Lys—
Val—Ser—Ser—Pro—Gln—Pro—Arg—Gly—Pro—Arg—OH

• XCF₃COOH

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Glucose-dependent insulinotropic peptide (GIP) (22-51) (human) (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the GIP (22-51) in water. We do not recommend storing the aqueous solution for more than one day.

Description

GIP (22-51) is a pro-atherogenic 30-amino acid peptide corresponding to residues 22-51 of the GIP precursor protein proGIP that has been found in human plasma.¹ It induces I κ B- α degradation and NF- κ B nuclear translocation in macrophage-differentiated THP-1 cells and isolated human aortic endothelial cells when used at a concentration of 1 μ M. *In vivo*, GIP (22-51) increases atherosclerotic lesion area and plaque formation in ApoE^{-/-} mice.

Reference

1. Masaki, T., Kodera, Y., Terasaki, M., et al. GIP_HUMAN[22-51] is a new proatherogenic peptide identified by native plasma peptidomics. *Sci. Rep.* **11(1)**, 14470 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/09/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM